Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gene therapy is emerging as a novel treatment for cancer. Preclinical data utilizing adenovirus vectors have been promising and several clinical trials employing this employing this vector are underway. Data from many phase I trials have established the safety of adenovirus vectors, but have not as yet demonstrated significant therapeutic benefit. In order to refine this approach, continuing efforts are being made to improve antitumor potency, efficiency of gene delivery and accuracy of vector targeting. It is anticipated that adenovirus-mediated gene therapy will be integrated with existing treatment modalities, including surgery, chemotherapy and radiotherapy, to facilitate improvement in cancer treatments in the future.


Journal article


Curr Opin Mol Ther

Publication Date





423 - 434


Adenoviridae, Clinical Trials as Topic, Genetic Therapy, Genetic Vectors, Humans, Neoplasms